Medicare Enrolled
Dr. Kenneth Lander, M.D.
Pulmonary Disease · Upland, PA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lander from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lander?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lander
Dr. Kenneth Lander is a pulmonary disease specialist in Upland, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Lander performed 4,122 Medicare services across 2,086 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lander received a total of $558,097 from 52 pharmaceutical and/or device companies across 1635 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lander is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 2% volume in PA
$558,097 industry payments
Medicare Practice Summary
Medicare Utilization ↗4,122
Medicare services
Top 2% in PA for pulmonary disease
2,086
Unique beneficiaries
$72
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~206 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,558 | $65 | $111 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
629 | $31 | $134 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
523 | $100 | $231 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
232 | $142 | $295 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
226 | $36 | $93 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
226 | $48 | $95 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
171 | $70 | $142 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
121 | $144 | $327 |
| Same-day hospital admission and discharge, low complexity Initial hospital care for a patient admitted and discharged on the same day, involving straightforward or low-level medical decision making. The visit requires at least 45 minutes of time if time is used to determine the level of service. |
84 | $81 | $294 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
77 | $98 | $134 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
69 | $107 | $197 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
52 | $14 | $38 |
| Sleep study with heart rate and breathing monitoring A sleep study that monitors heart rate, breathing patterns, and sleep duration. This test records physiological data while you sleep to assess your sleep quality and breathing function. |
47 | $125 | $525 |
| New patient office visit, complex (60-74 min) | 34 | $168 | $296 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
29 | $12 | $100 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
29 | $134 | $199 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
15 | $175 | $313 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$558,097
Total received (2018-2024)
Avg $79,728/year across 7 years
Top 0% in PA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
52
Companies
1,635
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$534,418 (95.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,134 (2.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$7,544 (1.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$163,301
2023
$162,007
2022
$53,349
2021
$50,177
2020
$24,315
2019
$30,660
2018
$74,287
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$160,210
GlaxoSmithKline, LLC.
$327
Mallinckrodt Hospital Products Inc.
$301
GENZYME CORPORATION
$288
JAZZ PHARMACEUTICALS INC.
$182
HARMONY BIOSCIENCES LLC
$178
Electromed, Inc.
$173
Axsome Therapeutics, Inc.
$169
Takeda Pharmaceuticals U.S.A., Inc.
$165
Boehringer Ingelheim Pharmaceuticals, Inc.
$145
Regeneron Healthcare Solutions, Inc.
$136
Insmed, Inc.
$132
Janssen Pharmaceuticals, Inc
$98
Bayer Healthcare Pharmaceuticals Inc.
$98
Harmony Biosciences Llc
$97
Actelion Pharmaceuticals US, Inc.
$93
ANI Pharmaceuticals, Inc.
$86
United Therapeutics Corporation
$59
Amgen Inc.
$51
Inspire Medical Systems, Inc.
$50
Baxter Healthcare
$47
Grifols USA, LLC
$39
Tactile Systems Technology Inc
$39
INOGEN, INC.
$37
Mylan Specialty L.P.
$37
Vifor Pharma, Inc.
$37
Merck Sharp & Dohme LLC
$14
Philips North America LLC
$13
Top 3 companies account for 98.5% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$453,082
Mallinckrodt LLC
$44,230
Mallinckrodt Enterprises LLC
$23,297
Boehringer Ingelheim Pharmaceuticals, Inc.
$14,088
Mallinckrodt Hospital Products Inc.
$5,388
Bayer HealthCare Pharmaceuticals Inc.
$3,032
GlaxoSmithKline, LLC.
$2,506
Insmed, Inc.
$998
GENZYME CORPORATION
$994
Janssen Pharmaceuticals, Inc
$935
Actelion Pharmaceuticals US, Inc.
$886
Regeneron Healthcare Solutions, Inc.
$710
United Therapeutics Corporation
$676
Harmony Biosciences LLC
$671
Philips Electronics North America Corporation
$638
Mylan Specialty L.P.
$632
Takeda Pharmaceuticals U.S.A., Inc.
$617
Sunovion Pharmaceuticals Inc.
$472
Grifols USA, LLC
$430
Axsome Therapeutics, Inc.
$425
Baxter Healthcare
$392
HARMONY BIOSCIENCES LLC
$359
JAZZ PHARMACEUTICALS INC.
$340
ANI Pharmaceuticals, Inc.
$301
Genentech USA, Inc.
$283
Electromed, Inc.
$240
Bayer Healthcare Pharmaceuticals Inc.
$165
Amgen Inc.
$153
COMSORT, Inc
$150
Circassia Pharmaceuticals Inc
$103
Harmony Biosciences Llc
$97
Exeltis, USA Inc.
$86
Inogen, Inc.
$80
Advanced Respiratory, Inc
$62
ADVANCED RESPIRATORY, INC
$61
Paratek Pharmaceuticals, Inc.
$58
Tactile Systems Technology Inc
$58
Inspire Medical Systems, Inc.
$50
Alexion Pharmaceuticals, Inc.
$43
Janssen Biotech, Inc.
$39
INOGEN, INC.
$37
Vifor Pharma, Inc.
$37
Novartis Pharmaceuticals Corporation
$33
Covis Pharma GmBH
$31
Astellas Pharma US Inc
$23
PFIZER INC.
$22
Merck Sharp & Dohme Corporation
$18
Shire North American Group Inc
$17
Merck Sharp & Dohme LLC
$14
Philips North America LLC
$13
Nabriva Therapeutics, plc
$13
Ipsen Biopharmaceuticals, Inc
$12
Top 3 companies account for 93.3% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (AK6) Vest Therapy · ACTHAR · AIRSUPRA · ALVESCO · ANORO · ANORO ELLIPTA · ARALAST · AREXVY · Adempas · Arikayce · BEVESPI AEROSPHERE · BREO · BREZTRI · BREZTRI AEROSPHERE · CUVITRU · Cresemba · DARZALEX · DUAKLIR PRESSAIR · DUPIXENT · ELIQUIS · Esbriet · FARXIGA · FASENRA · Flexitouch Plus · GLASSIA · HYQVIA · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · INSPIRE · LONHALA MAGNAIR · LUMIZYME · NONE · NUCALA · NUZYRA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · PURIFIED CORTROPHIN GEL · Prolastin-C · Prolastin-C Liquid · Respiratoriy Care Undiv · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Sunosi · TAGRISSO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · Trilogy 100 · ULTOMIRIS · UPTRAVI · Ultomiris · Utibron · Veltassa · WAKIX · WINREVAIR · Wakix · Wellcentive Undiv · XARELTO · XOLAIR · XYWAV · Xembify · Xenleta · Xofigo · Xolair · YUPELRI · Yupelri · ZERBAXA · Zemaira · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (96%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for pulmonary disease in PA.
Geographic Context
Pulmonary diseases within 10 mi
259
Per 100K population
45.0
County median income
$88,576
Nearest hospital
CROZER CHESTER MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lander is a clinical cardiology specialist, with above-average Medicare volume (top 2% in PA), with speaking/promotional industry engagement in the top 0% of PA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lander experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Lander performed 1,558 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lander receive payments from pharmaceutical companies?
Yes. Dr. Lander received a total of $558,097 from 52 companies across 1,635 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lander's costs compare to other pulmonary diseases in Upland?
Dr. Lander's average Medicare payment per service is $72. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lander) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Upland
Browse pulmonary diseases in Upland ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in PA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in PA
Which PA pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Mallinckrodt LLC Payments to Doctors
See all physicians who received payments from Mallinckrodt LLC.
By company
Mallinckrodt Enterprises LLC Payments to Doctors
See all physicians who received payments from Mallinckrodt Enterprises LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology